CMCaroline Morbieu

Caroline Morbieu

*This is an algorithmically generated author record based on publicly available information.

Caroline Morbieu has a total of 219 co-authors. Here are the top co-authors by number of shared publications:

  • Matthieu Mahévas

    Service de Médecine Interne, Centre National de Référence des Cytopénies Auto‐Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP‐HP) Université Paris Est Créteil Créteil France

    4 shared publications
  • Nicolas Roche

    Service de Pneumologie, Hôpital Cochin, AP-HP, Université Paris Cité, UMR 1016, Institut Cochin, Paris, France

    3 shared publications
  • Anh Tuan Dinh-Xuan

    Department of Respiratory and Sleep Medicine, Cochin Hospital, University Paris Cite, Paris, France

    2 shared publications
  • Benjamin Terrier

    Service de Médecine Interne, Hôpital Cochin, Paris, France

    2 shared publications
  • Bertrand Godeau

    Department of Internal Medicine and Clinical Immunology, coordinating center of the national reference center for adult' immune cytopenias, Henri Mondor university hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Paris, France

    2 shared publications
  • Frédérique Aubourg

    Department of Respiratory and Sleep Medicine, INSERM UMR1343, Assistance Publique—Hôpitaux de Paris, Cochin Hospital, Université Paris Cité, 75006 Paris, France

    2 shared publications

Latest Publications

  • Open Access

    Unilateral Facial Swelling as the Inaugural Sign of Anti‐NPX2 Dermatomyositis: A Diagnostic Challenge in Oral Medicine

    by Françoise Tilotta, Hadrien Le Vayer, Olivier Bory, Caroline Morbieu, Loredana Radoi

    A 41‐year‐old female patient in apparent good health presented to the dental emergency department with a 6‐week history of painless, nonpruritic left facial swelling, and dotted with purplish patches. She had consulted different physicians and dentists and received several ineffective treatments. After ruling out an oral cause, standard blood tests were initially prescribed. They showed an isolated elevation of creatine phosphokinase (CPK). Muscular weakness of the left arm and leg, pain on mobilization of the left thigh, and erythematous plaques on the left body then appeared. Infectious, granulomatous, and autoimmune diseases were investigated. Magnetic resonance imaging (MRI) showed diffuse muscle infiltration, suggestive of myositis. Myositis‐specific dot immunoassay identified antinuclear matrix protein 2 (NXP2) autoantibodies, enabling the diagnosis of dermatomyositis. The inaugural orofacial manifestations of dermatomyositis can be confused with pathologies of dental cause, such as cellulitis. In the absence of local warning signs, oral health professionals must consider a systemic etiology and rapidly refer the patient to avoid patient wandering.

  • Open Access

    Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

    by Paul Bastard, Sara E. Vazquez, Jamin Liu, Matthew T. Laurie, Chung Yu Wang, Adrian Gervais, Tom Le Voyer, Lucy Bizien, Colin Zamecnik, Quentin Philippot, et al.

    Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population.


  • Open Access

    Distal Lung Inflammation Assessed by Alveolar Concentration of Nitric Oxide Is an Individualised Biomarker of Severe COVID-19 Pneumonia

    by Thông Hua-Huy, Sven Günther, Christine Lorut, Marielle Subileau, Frédérique Aubourg, Caroline Morbieu, Jonathan Marey, Joëlle Texereau, Isabelle Fajac, Luc Mouthon, et al.

    Pulmonary sequelae as assessed by pulmonary function tests (PFTs) are often reported in patients infected by SARS-CoV-2 during the post-COVID-19 period. Little is known, however, about the status of pulmonary inflammation during clinical recovery after patients’ discharge from the hospitals. We prospectively measured PFTs coupled with the exhaled nitric oxide (NO) stemming from the proximal airways (FeNO) and the distal lung (CaNO) in 169 consecutive patients with varying degrees of the severity of COVID-19 six weeks to one year after acute infection by SARS-CoV-2. The proportions of patients with abnormal PFTs, defined as the presence of either obstructive/restrictive patterns or impaired lung gas transfer, or both, increased with the severity of the initial lung disease (15, 30, and 52% in patients with mild, moderate, and severe COVID-19). FeNO values remained within normal ranges and did not differ between the three groups of patients. CaNO, however, was significantly higher in patients with severe or critical COVID-19, compared with patients with milder forms of the disease. There was also an inverse relationship between CaNO and DLCO. We conclude that the residual inflammation of the distal lung is still present in the post-COVID-19 follow-up period, in particular, in those patients with an initially severe form of COVID-19. This long-lasting alveolar inflammation might contribute to the long-term development of pulmonary fibrosis and warrants the regular monitoring of exhaled NO together with PFTs in patients with COVID-19.


  • Open Access

    Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19

    by Thông Hua-Huy, Christine Lorut, Frédérique Aubourg, Caroline Morbieu, Jonathan Marey, Joëlle Texereau, Isabelle Fajac, Luc Mouthon, Nicolas Roche, Anh Tuan Dinh-Xuan


  • Vascularites à IgA associées aux maladies inflammatoires chroniques de l’intestin : étude observationnelle multicentrique rétrospective de 43 patients

    by C. Rasmussen, V. Abitbol, K. El Karoui, A. Bourrier, R. Paule, S. Koch, F. Maurier, D. Laharie, F. Aubin, M. Fumery, et al.

  • Open Access

    No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial

    by Matthieu Mahévas, Viet-Thi Tran, Mathilde Roumier, Amélie Chabrol, Romain Paule, Constance Guillaud, Sébastien Gallien, Raphael Lepeule, Tali-Anne Szwebel, Xavier Lescure, et al.

    Background: Treatments are urgently needed to prevent respiratory failure and deaths from coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide attention because of positive results from small studies. Methods: We used data collected from routine care of all adults in 4 French hospitals with documented SARS-CoV-2 pneumonia and requiring oxygen ≥ 2 L/min to emulate a target trial aimed at assessing the effectiveness of HCQ at 600 mg/day. The composite primary endpoint was transfer to intensive care unit (ICU) within 7 days from inclusion and/or death from any cause. Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results: This study included 181 patients with SARS-CoV-2 pneumonia; 84 received HCQ within 48 hours of admission (HCQ group) and 97 did not (no-HCQ group). Initial severity was well balanced between the groups. In the weighted analysis, 20.2% patients in the HCQ group were transferred to the ICU or died within 7 days vs 22.1% in the no-HCQ group (16 vs 21 events, relative risk [RR] 0.91, 95% CI 0.47–1.80). In the HCQ group, 2.8% of the patients died within 7 days vs 4.6% in the no-HCQ group (3 vs 4 events, RR 0.61, 95% CI 0.13–2.89), and 27.4% and 24.1%, respectively, developed acute respiratory distress syndrome within 7 days (24 vs 23 events, RR 1.14, 95% CI 0.65–2.00). Eight patients receiving HCQ (9.5%) experienced electrocardiogram modifications requiring HCQ discontinuation. Interpretation: These results do not support the use of HCQ in patients hospitalised for documented SARS-CoV-2-positive hypoxic pneumonia.


  • Un très mauvais voyage

    by C. Morbieu, G. Rollin, N. Saada, F. Botterel, N. Limal, R. Lepeule, M. Michel, V. Sobanski


  • Systematic detection of portal or splenic vein thrombosis after splenectomy for immune cytopenia

    by Caroline Morbieu, Francesco Brunetti, Laurence Baranès, Laetitia Languille, Nicolas Limal, Valentine Loustau, Philippe Bierling, Marc Michel, Bertrand Godeau, Matthieu Mahévas


  • Open Access

    Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia

    by Guillaume Voiriot, Benoit Visseaux, Johana Cohen, Liem Binh Luong Nguyen, Mathilde Neuville, Caroline Morbieu, Charles Burdet, Aguila Radjou, François-Xavier Lescure, Roland Smonig, et al.

    Multiplex polymerase chain reaction (mPCR) enables recovery of viruses from airways of patients with community-acquired pneumonia (CAP), although their clinical impact remains uncertain. Among consecutive adult patients who had undergone a mPCR within 72 hours following their admission to one intensive care unit (ICU), we retrospectively included those with a final diagnosis of CAP. Four etiology groups were clustered: bacterial, viral, mixed (viral-bacterial) and no etiology. A composite criterion of complicated course (hospital death or mechanical ventilation > 7 days) was used. A subgroup analysis compared patients with bacterial and viral-bacterial CAP matched on the bacterial pathogens. Among 174 patients (132 men [76 %], age 63 [53–75] years, SAPSII 38 [27;55], median PSI score 106 [78;130]), bacterial, viral, mixed and no etiology groups gathered 46 (26 %), 53 (31 %), 45 (26 %) and 30 (17 %) patients, respectively. Virus-infected patients displayed a high creatine kinase serum level, a low platelet count, and a trend toward more frequent alveolar-interstitial infiltrates. A complicated course was more frequent in the mixed group (31/45, 69 %), as compared to bacterial (18/46, 39 %), viral (15/53, 28 %) and no etiology (12/30, 40 %) groups (p < 0.01). In multivariate analysis, the mixed (viral-bacterial) infection was independently associated with complicated course (reference: bacterial pneumonia; OR, 3.58; CI 95 %, 1.16–11; p = 0.03). The subgroup analysis of bacteria-matched patients confirmed these findings. Viral-bacterial coinfection during severe CAP in adults is associated with an impaired presentation and a complicated course.


  • Néphropathie à IgA compliquée d’un syndrome néphrotique révélée par une tuberculose disséminée

    by Caroline Morbieu, Pierre-Antoine Michel, Isabelle Brocheriou, Ana Canestri, Jean-Jacques Boffa

    A 27-year-old man without any medical history presented concomitantly a pulmonary and urinary tuberculosis and a nephrotic syndrome with hematuria and renal failure. The renal biopsy showed increased mesangial matrix, few focal segmental lesions, and IgA deposits confirming the diagnosis of IgA nephropathy. Nephrotic syndrome remission occurred quickly after antituberculous treatment. The association between tuberculosis and IgA nephropathy has been previously reported in 9 patients. Renal outcome was always favorable with antituberculous treatment. No relapse occurred, with a maximal follow-up of 42 months. Here, we discuss this singular association and previous similar cases.